Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) major shareholder Morningside Venture Investment sold 50,000 shares of the company's stock in a transaction on Wednesday, January 25th. The shares were sold at an average price of $6.85, for a total transaction of $342,500.00. Following the completion of the transaction, the insider now owns 5,662,993 shares in the company, valued at $38,791,502.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Morningside Venture Investment also recently made the following trade(s):

• On Monday, January 23rd, Morningside Venture Investment sold 80,000 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.81, for a total transaction of $544,800.00.
• On Tuesday, January 17th, Morningside Venture Investment sold 6,114 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.79, for a total transaction of $41,514.06.
• On Thursday, January 12th, Morningside Venture Investment sold 5,000 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.77, for a total transaction of $33,850.00.
• On Thursday, January 5th, Morningside Venture Investment sold 12,162 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.97, for a total transaction of $84,769.14.

Kezar Life Sciences Stock Performance

Shares of Kezar Life Sciences stock traded up $0.17 during trading on Friday, reaching $6.90. The company's stock had a trading volume of 348,342 shares, compared to its average volume of 679,713. Kezar Life Sciences, Inc. has a 52 week low of $4.30 and a 52 week high of $18.55. The business's 50-day moving average price is $6.99 and its 200-day moving average price is $8.27. The company has a quick ratio of 31.15, a current ratio of 31.15 and a debt-to-equity ratio of 0.03. The firm has a market cap of $471.81 million, a PE ratio of -6.72 and a beta of 0.23.

Analyst Ratings Changes

Separately, Wells Fargo & Company reduced their target price on shares of Kezar Life Sciences from $17.00 to $14.00 and set an "overweight" rating for the company in a research report on Tuesday, January 3rd.

Institutional Investors Weigh In On Kezar Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in shares of Kezar Life Sciences by 22.9% in the third quarter. Bank of New York Mellon Corp now owns 181,850 shares of the company's stock worth $1,566,000 after acquiring an additional 33,866 shares during the last quarter. Robeco Institutional Asset Management B.V. bought a new position in shares of Kezar Life Sciences in the third quarter worth about $68,000. California State Teachers Retirement System lifted its holdings in shares of Kezar Life Sciences by 6.7% in the third quarter. California State Teachers Retirement System now owns 59,768 shares of the company's stock worth $515,000 after acquiring an additional 3,744 shares during the last quarter. BNP Paribas Arbitrage SNC lifted its holdings in shares of Kezar Life Sciences by 595.1% in the third quarter. BNP Paribas Arbitrage SNC now owns 114,545 shares of the company's stock worth $986,000 after acquiring an additional 98,066 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Kezar Life Sciences by 381.3% in the third quarter. State Street Corp now owns 3,537,701 shares of the company's stock worth $30,460,000 after acquiring an additional 2,802,611 shares during the last quarter. Institutional investors own 84.03% of the company's stock.

Kezar Life Sciences Company Profile

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.

See Also

• Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market
• PCE Indicates Slowdown In Spending, Economy Weakens

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.